2018 Annual Sessions

Apr 11, 2018 ‐ Apr 14, 2018


Standard: $250.00
Non-member Attendee 2018: $125.00
Non-member Allied Health/Non-Physician: $75.00
Non-member Student/Trainee : $50.00

Sessions

 2018 Leadership Orientation 2018 Leadership Orientation

Preview Available

2018 Leadership Orientation

Apr 10, 2017 2:00pm ‐ Apr 10, 2017 4:30pm

Identification: OR01


ORAL SESSION 01 - Stop It Without Bleeding: Mechanisms of Stroke in MCS

Apr 11, 2018 8:30am ‐ Apr 11, 2018 10:00am

Identification: OS01

(1) Blood Pressure Management Ameliorates the Severity of Neurological Events
Jeffrey Teuteberg, MD

(2) Quantifying the Devastation From Stroke During Support With Continuous Flow Pumps: An Intermacs Analysis
James Kirklin, MD

(3) Neurocognitive Deficits are Prevalent in Ambulatory Patients Living with Left Ventricular Assist Devices
Hussain Khalid, MD

(4) Risk of Thromboembolic Events Among Heart Transplant Recipients Bridged with Durable Mechanical Circulatory Support Devices Receiving Anticoagulation Reversal Agents at Time of Transplant
Sandip Zalawadiya, MD

(6) Stroke After LVAD: Does Age Matter? A Sex-based Analysis
Vanessa Blumer, MD 

Speaker(s):
Tags: MCS NHSAH PHARM

ORAL SESSION 02 - Thinking Inside The Box: DCD Donation and Ex-vivo Heart Perfusion

Apr 11, 2018 8:30am ‐ Apr 11, 2018 10:00am

Identification: OS02

(7) Non Ischemic Heart Preservation
Johan Nilsson, MD. PhD, Professor

(8) Early Outcomes from DCD Heart Transplantation: A Single Centre Experience
Aravinda Page, MBBChir

(9) Donation After Circulatory Death (DCD) Heart Transplantation in Australia: An Update of Current Practises and Outcomes
Hong Chee Chew, MBBS, MS

(10) Midterm Followup of Heart Transplantation With Ex vivo Normothermic Preservation Using Extended Criteria Donor Hearts
Diana  García Sáez,MD

(11) Prolonged Donation Withdrawal Ischaemic Time (DWIT) Does Not Impact on DCD Heart Transplant Outcomes
Simon Messer,  MBChB MRCS

(12) Post-Transplant Assessment of Donation after Circulatory Death (DCD) Cardiac Allografts with MRI - An Update
Evgeny Pavlusnkov, MD, PhD

Speaker(s):

ORAL SESSION 03 - Novel Insights About Antibodies in Lung Transplantation

Apr 11, 2018 8:30am ‐ Apr 11, 2018 10:00am

Identification: OS03

(13) Is the New ISHLT Criteria for Pulmonary Antibody-mediated Rejection Also a Severity Indicator?
Hannah Valantine, MD for Adam Cochrane, PharmD

(14) Risk Factors for the Development of Donor-specific Antibodies and Their Impact on Outcomes After Lung Transplantation
Kevin Tsui, MD

(15) Antibody-mediated Rejection: Should We Wait for Clinical Diagnosis?
Sean Agbor-Enoh, MD

(16) Elevated Donor-Derived Cell-Free DNA (ddcfDNA) as an Early Risk Factor for the Development and Persistence of De Novo Donor Specific HLA Antibody
Annette Jackson, PhD

(17) Important HLA and Non-HLA Pre-Transplant Determinants Associated with the Development of De Novo Donor Specific Antibody After Lung Transplantation
Aiwen Zhang, PhD

(18) Feasibility of Avoiding Higher Risk Epitope and Allele HLA Mismatch to Reduce de novo Donor Specific Antibody (dnDSA) in Lung Transplantation
Ricardo Zamel, PhD 

Speaker(s):
Tags: LTX BSTR PATH

ORAL SESSION 04 - Immunosuppression in Heart Transplantation: Lessons Learned

Apr 11, 2018 8:30am ‐ Apr 11, 2018 10:00am

Identification: OS04

(19) Multicenter Study to Determine Up to 5 Year Clinical Outcome of Heart Transplant Recipient Receiving Rituximab Versus Placebo Outcomes in Subjects Previously Randomized in the CTOT-11 Study
Randall Starling, MD, MPH

(20) Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance (Schedule): Results After 6 Years of Follow-up
Arne Andreassen, MD, PhD

(21) TICTAC 10: Ten Year Follow-up of the Tacrolimus in Combination Tacrolimus Alone Compared Trial
David Baran, MD

(22) Clinical Outcomes Associated With mTORi Initiation in Adult Heart Transplant: An ISHLT Registry Analysis
Juan Duero Posada, MD

(23) Quantiferon Monitor Assay Identifies Over-Immunosuppressed Patients with Adverse Outcomes After Heart Transplantation: Towards the Definition of a Phenotype of Immune Frailty
Luciano Potena, MD, PhD

(24) 5-Year Outcome of Renal Function with Patients on Renal-Sparing Protocol After Heart Transplantation
Jignesh Patel, MD, PhD

Speaker(s):

ORAL SESSION 05 - Don’t Go Breaking My Heart: The Assessment, Treatment and Implications of Psychosocial Risk Factors

Apr 11, 2018 8:30am ‐ Apr 11, 2018 10:00am

Identification: OS05

(25) Variability in Depressive Symptoms and Its Multilevel Correlates in Heart Transplant Recipients: Results From the International Cross-sectional BRIGHT Study
Nathalie Duerinchx, MSN, PhDc

(26) Pre-transplant Distress and Risk of Early Death in UK Cardiothoracic Transplant Recipients
Zoey Malpus

(27) Psychosocial Assessment for LVAD Candidates: A National Survey
Malachy Clancy, MOT,PhD (c)

(28) Psychosocial Risk in LVAD Candidates: Preliminary Evaluation of Validity and Reliability of mPACT
Megan Maltby, MSW

(29) Predictors of Posttraumatic Growth Post Lung Transplant
Melissa Sanchez, BScHons PGDip MSc DClinPsych

(30) PTSD Following Heart and Lung Transplant: Outcome of Those Receiving Trauma-Focused Cognitive Behavioral Therapy
Liz Painter, MA MSc

Speaker(s):
Tags: MCS NHSAH HTX

ORAL SESSION 06 - Building a Better Transplant

Apr 11, 2018 8:30am ‐ Apr 11, 2018 10:00am

Identification: OS06

(31) Mitochondrial Transplantation Prolongs Cold Preservation Time in Murine Cardiac Transplantation
Kamila Moskowitzova, MD

(218) Intracoronary Implantation of Post-GCSF Stimulation Circulation-derived Autologous CD34+ Cells Reverses Cardiac Remodeling in Patients With End-stage Diffuse Coronary Artery Disease (CAD) - Phase I Early and Long-term Results
Fan-Yen Lee, MD

(33) Knockout of the M33 Receptor Gene in Murine Cytomegalovirus is Associated With Decreased Levels of Cardiac Allograft Vasculopathy in a Murine Aortic Transplant Model
Christian Heim, MD, PhD

(35) Primary LV Unloading with a Trans-valvular Axial Flow Pump Reduces Infarct Size by Increasing Myocardial Levels of Stromal Derived Factor One Alpha (SDF-1a) in Acute Myocardial Infarction and Limits the Development of Ischemic Heart Failure
Michele Esposito, MD

(36) Pre-Transplant Serum Exosome Proteomics Differentiates Right and Left Ventricular Primary Graft Dysfunction
Barry Fine, MD, PhD

(220) Variable Cell-free DNA Characteristics With Different Acute Rejection Phenotypes
Sean Agbor-Enoh, MD

Speaker(s):
  • Kamila Moskowitzova, MD, Boston Children's Hospital and Harvard Medical School
  • Fan-Yen Lee, MD, Chang Gung Mem Hosp
  • Christian Heim, MD PhD, University of Erlangen, Erlangen, Germany
  • Michele Esposito, MD, Tufts Medical Center
  • Barry Fine, MD PhD, Columbia University, New York, NY, United States
  • Sean Agbor-Enoh, MD, PhD, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD, United States
Tags: MCS BSTR PATH HTX

ORAL SESSION 07 - Cutting Edge CTEPH: From Metabolomics to Surgical Technique

Apr 11, 2018 8:30am ‐ Apr 11, 2018 10:00am

Identification: OS07

(37) Pre-PTE Pulmonary Artery Elastance, Right Ventricular Elastance, and RV-PA Coupling Predict Post-Operative Length of Stay and Hemodynamics
Francisco Contijoch, PhD

(38) Metabolomics Analysis in Chronic Thromboembolic Pulmonary Hypertension
Gustavo Heresi, MD, MS

(39) A Comparison of Short Term Outcomes of Minimally Invasive versus Sternotomy Pulmonary Thromboendarterectomy
Michael Madani, MD

(40) Impact on Outcomes with Extra-Corporeal Life Support (ECLS) After Complicated Pulmonary Thrombo-Endarterectomy
Herma Nair, MD

(42) The Incidence and Identification of Chronic Thromboembolic Disease in Patients Presenting with Acute Pulmonary Embolism
Laura DiChiacchio, MD, PhD

Speaker(s):
Tags: MCS CTEPH BSTR

PLENARY 1 - Opening Plenary Session

Apr 11, 2018 10:30am ‐ Apr 11, 2018 12:30pm

Identification: PL01

Welcome/Program Chair Report
Christian Benden, MD, FCCP

Thoracic Registry Report
Josef Stehlik, MD, MPH

MCSD Registry Reports
Daniel J. Goldstein 

JHLT Editor's Report
Mandeep Mehra, MD, MBBS, FACC, FACP

Presidential Address
Andrew Fisher, PhD, FRCP

(43)  Molecular Diagnosis of Rejection Phenotypes in 889 Heart Transplant Biopsies: The INTERHEART Study
Philip Halloran, PhD, MD

Interactive Discussant for Presentation 43
Lori West, MD, D.Phil 

(44)  Benefits of Early Everolimus-Based Quadruple Immunosuppression Early After Lung Transplantation - Results of 4EVERLUNG, a Prospective Randomized Multicenter Trial
Jens Gottlieb, Prof. Dr. med.

Interactive Discussant for Presentation 44
Roger Yusen, MD, MPH

Lifetime Achievement Award Laudation
Robert Kormos, MD

Lifetime Achievement Award Acceptance
O. Howard Frazier, MD

Speaker(s):
  • Christian Benden, MD, FCCP, University Hospital Zurich
  • Robert Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
  • Daniel Goldstein, MD,FACS,FACC, Montefiore Medical Center, Bronx, NY, United States
  • Roger Yusen, MD, MPH, Washington Univ Sch Med
  • Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany
  • Lori West, MD, D.Phil, University of Alberta
  • Philip Halloran, MD, PhD, University of Alberta, Edmonton, AB, Canada
  • Andrew Fisher, FRCP, PhD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
  • Mandeep Mehra, MD, FRCP, FACC, FESC, Brigham and Women's Hospital, Boston, MA, United States
  • Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, United States
  • O. Howard Frazier, MD, Texas Heart Institute
Tags: ALL

SYMPOSIUM 01 - The Devil Wears Prada - The Role of the RV in Advanced Heart Failure and LVADs

Apr 11, 2018 2:00pm ‐ Apr 11, 2018 3:41pm

Identification: SYM01

Pathogenesis of RV Failure Due to Left Heart Disease
Ryan Tedford,  MD, FACC, FAHA

The Importance of Exercise Physiology in the Assessment of RV Function in Heart Failure Patients
Marco Guazzi, MD

Defining Biventricular Failure: What is the Best Modality?
Maria Crespo-Leiro

Systemic Venous Congestion From RV Failure as a Fundamental Stimulus for Dysfunction and Damage of Vital Organs
Paolo Colombo, MD

Non-Surgical Treatment of RV Failure Post LVAD
Sandra Eifert, MD

CASE PRESENTATION: Unexpected RV Failure with Persistent Pulmonary Hypertension Following LVAD: What Now?
Steven Hsu, MD

Drug Therapies for Pulmonary Hypertension are Needed to Target the Right Ventricle
Marc Simon, MD

Surgical Treatment of RV Failure Post LVAD
Francis Pagani, MD, PhD

Pulsatile BiVAD: Reality or Fantasy?
Bastian Schmack, MD

Speaker(s):
  • Ryan Tedford, MD, FACC, FAHA, Medical University of South Carolina, Charleston, SC, United States
  • Marco Guazzi, MD, PhD, IRCCS Pol San Donato, Milan, Italy
  • Maria Crespo, MD, University of Pennsylvania, Philadelphia, PA, United States
  • Paolo Colombo, MD, Columbia University Medical Center, New York, NY, United States
  • Sandra Eifert, MD, LMU University clinic Munich, Dept. of cardiac surgery Germany
  • Steven Hsu, MD, Johns Hopkins University, Baltimore, MD, United States
  • Marc Simon, MD, University of Pittsburgh
  • Francis Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, United States
  • Bastian Schmack, MD, Royal Brompton and Harefield NHS Foundation Trust
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content